| 000 | 01584 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515052457.0 | ||
| 264 | 0 | _c20070327 | |
| 008 | 200703s 0 0 eng d | ||
| 022 | _a0022-510X | ||
| 024 | 7 |
_a10.1016/j.jns.2006.10.018 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLin, Juei-Jueng | |
| 245 | 0 | 0 |
_aGenetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease. _h[electronic resource] |
| 260 |
_bJournal of the neurological sciences _cJan 2007 |
||
| 300 |
_a130-4 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGenetic Predisposition to Disease _xepidemiology |
| 650 | 0 | 4 | _aHomozygote |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aPeptidyl-Dipeptidase A _xgenetics |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 |
_aPsychoses, Substance-Induced _xepidemiology |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aYueh, Kuo-Chu | |
| 700 | 1 | _aLin, Shinn-Zong | |
| 700 | 1 | _aHarn, Horng-Jyh | |
| 700 | 1 | _aLiu, Jung-Tung | |
| 773 | 0 |
_tJournal of the neurological sciences _gvol. 252 _gno. 2 _gp. 130-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jns.2006.10.018 _zAvailable from publisher's website |
| 999 |
_c16763419 _d16763419 |
||